Exploring The Promise Of Biomarkers For Acute Kidney InjuryⅠ

Acute kidney injury (AKI) is a complex challenge with diverse pathological mechanisms and causes. Current detection methods rely primarily on serum creatinine, which exhibits significant limitations in specificity and raises issues with late-stage detection of renal injury.

Click to Cistanche for kidney disease

In this review, the authors present a recent and comprehensive summary of progress in identifying new biomarker candidates and ideal standard AKI biomarkers in blood and urine, such as specificity of kidney injury, mechanistic insights, Prognosis, and affordability. Recently discovered biomarkers not only indicate the site of injury but also provide valuable insights into a range of pathological processes, including reduced glomerular filtration rate, tubular function, inflammation, and adaptive responses to injury.

AKI biomarkers are increasingly used clinically as relevant tools to differentiate between acute tubular necrosis and other acute kidney diseases. Furthermore, these biomarkers may provide important insights into the risk of CKD progression and kidney transplantation. Integrating these biomarkers into clinical practice has the potential to improve early diagnosis of AKI and revolutionize the design of clinical trials, providing valuable endpoints for therapeutic intervention and enhancing patient care and outcomes.  

1 Introduction

Currently, international guidelines for the diagnosis and stratification of AKI are based only on the loss of glomerular function, assessed by serum creatinine (SCr) dose and urine output. This has been the norm for more than 100 years. Although these guidelines and classifications (e.g., RIFLE, AKIN, and KDIGO 2012) are critical for defining, stratifying, and treating patients, it is clear that they focus primarily on renal function and excretion and lack precision on underlying mechanisms of injury.

Diseases like AKI, which involve multiple aspects such as etiology, pathophysiological mechanisms, prognosis, and treatment, should not be reduced to a single biochemical test. SCr may not be an ideal biomarker of acute kidney injury for several reasons. First, creatinine production is not always a reflection of steady state; it is a product of creatine and creatine phosphate metabolism within muscle cells and varies with factors such as patient age, gender, muscle mass, and protein intake.

This variability also emphasizes that creatinine requires time to accumulate, making it a delayed biomarker. Furthermore, it is not specific for the diagnosis of renal or tubular injury; elevated creatinine levels are seen in all phenotypes from prerenal azotemia to obstructive disease.

Therefore, its elevation does not provide substantial evidence regarding the location, cause, or treatment of the injury. Finding ideal biomarkers is a challenge, especially in the context of acute kidney injury. Not only should it reflect the specificity of renal injury and provide mechanistic insights, but it should also be reproducible, have prognostic capabilities, and be affordable and non-invasive.

Biomarkers are based on the BEST (Biomarkers, Endpoints, and Other Tools) joint working group of the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH). Tools such as Endpoint S) resources are defined and classified, describing their functions from diagnosis and monitoring to prognostic and predictive value, resulting in biomarkers for clinical and surrogate endpoints.

Ideally, biomarkers should be validated in multicenter cohorts followed by prospective cohorts focused on specific outcomes. Following these validation steps, the biomarker should also be tested in specifically designed clinical trials to ensure its role in changing patient outcomes in clinical practice. Finally, in the case of AKI, an ideal biomarker may not replace SCr and urine output but should be considered of additional value, as illustrated by an insightful model proposed by Oliveira et al..

In this model, these three elements are combined to dynamically visualize real damage, combining impairment with dysfunction. This concept brings us closer to the fact that the etiology may start from the initial stages of injury, manifested by an increase in biomarkers, while function remains preserved, manifested by normal serum creatinine and urine output.

At the other end of the disease spectrum, we find a dysfunctional etiology, leading to elevated creatinine and reduced urine output, but without impairment or increased biomarkers such as reversible volume loss. In this review, the authors provide a comprehensive summary of AKI biomarkers, their clinical applications, prognostic value, and potential to improve risk stratification and guide treatment.

How Does Cistanche Treat Kidney Disease?

Cistanche is a traditional Chinese herbal medicine used for centuries to treat various health conditions, including kidney disease. It is derived from the dried stems of Cistanche deserticola, a plant native to the deserts of China and Mongolia. The main active components of cistanche are phenylethanoid glycosides, echinacoside, and acteoside, which have been found to have beneficial effects on kidney health.

Kidney disease, also known as renal disease, is a condition in which the kidneys are not functioning properly. This can result in a buildup of waste products and toxins in the body, leading to various symptoms and complications. Cistanche may help treat kidney disease ase through several mechanisms.

Firstly, cistanche has been found to have diuretic properties, meaning it can increase urine production and help eliminate waste products from the body. This can help relieve the burden on the kidneys and prevent the buildup of toxins. By promoting diuresis, cistanche may also help Reduce high blood pressure, a common complication of kidney disease.

Moreover, cistanche has been shown to have antioxidant effects. Oxidative stress, caused by an imbalance between the production of free radicals and the body's antioxidant defenses, plays a key role in the progression of kidney disease. ies help neutralize free radicals and reduce Oxidative stress, thereby protecting the kidneys from damage. The phenylethanoid glycosides found in cistanche have been particularly effective in scavenging free radicals and inhibiting lipid peroxidation.

Additionally, cistanche has been found to have anti-inflammatory effects. Inflammation is another key factor in the development and progression of kidney disease. Cistanche's anti-inflammatory properties help reduce the production of pro-inflammatory cytokines and inhibit the activation of inflammation mandatory pathways, thus alleviating inflammation in the kidneys.

Furthermore, cistanche has been shown to have immunomodulatory effects. In kidney disease, the immune system can be dysregulated, leading to excessive inflammation and tissue damage. Cistanche helps regulate the immune response by modulating the production and activity of immune cells, such as T cells and macrophages. This immune regulation helps reduce inflammation and prevent further damage to the kidneys.

Moreover, cistanche has been found to improve renal function by promoting the regeneration of renal tubes with cells. Renal tubular epithelial cells play a crucial role in the filtration and reabsorption of waste products and electrolytes. In kidney disease, these cells can be damaged, leading to damaged renal function. Cistanche's ability to promote the regeneration of these cells helps restore proper renal function and improve overall kidney health.

In addition to these direct effects on the kidneys, cistanche has been found to have beneficial effects on other organs and systems in the body. This holistic approach to health is particularly important in kidney disease, as the condition often affects multiple organs and systems. che has been shown to have protective effects on the liver, heart, and blood vessels, which are commonly affected by kidney disease. By promoting the health of these organs, cistanche helps improve overall kidney function and prevent further complications.

In conclusion, cistanche is a traditional Chinese herbal medicine used for centuries to treat kidney disease. Its active components have diuretic, antioxidant, anti-inflammatory, immunomodulatory, and regenerative effects, which help improve renal function and protect the kidneys from further damage. , cistanche has beneficial effects on other organs and systems, making it a holistic approach to treating kidney disease.